Cantor Fitzgerald Reiterates Overweight on Aptose Biosciences, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Aptose Biosciences (NASDAQ:APTO) and maintained a $38 price target.
September 07, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Aptose Biosciences and maintained a $38 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Aptose Biosciences. The maintained price target of $38 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100